REFERENCES
- Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS. 1999;13:F35–F43.
- Lucas G, Chaisson R, Moore R. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;13:81–87.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341(25):1865–1873.
- Montaner J, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. JAMA. 1998;279:930–937.
- Podzamczer D, Ferrer E, Consiglio E, et al. 36-week results of a randomized, open, multicenter trial comparing Combivir (AZT/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients. (COMBINE study). Paper presented at: Eighth Conference on Retroviruses and Opportunistic Infections; February 4–8, 2001; Chicago, Illinois. Abstract 327.
- Pollard R. Factors predictive of durable HIV suppression in randomized double-blind trial with nevirapine (NVP), zidovudine (ZDV), and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS. Paper presented at: Seventh Conference on Retroviruses and Opportunistic In-fections; 2000; San Francisco. Abstract 517.
- van Heeswijk RPG, Veldkamp Al, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14:F77–F82.
- Leitz G, Robinson P. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen. AIDS. 2000;14:468–469.
- van der Valk M, Kastelein J, Murphy R, et al. Nevirapine containing potent antiretroviral therapy results in an anti-atherogenic plasma lipid profile: Results from the Atlantic study. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4–8, 2001; Chi-cago., Illinois. Abstract 654B.